288 related articles for article (PubMed ID: 16397230)
61. Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
Takahara K; Azuma H; Sakamoto T; Kiyama S; Inamoto T; Ibuki N; Nishida T; Nomi H; Ubai T; Segawa N; Katsuoka Y
Anticancer Res; 2009 Jul; 29(7):2497-505. PubMed ID: 19596919
[TBL] [Abstract][Full Text] [Related]
62. T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin.
Wolfgang CD; Essand M; Lee B; Pastan I
Cancer Res; 2001 Nov; 61(22):8122-6. PubMed ID: 11719440
[TBL] [Abstract][Full Text] [Related]
63. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
64. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
Perego P; Ciusani E; Gatti L; Carenini N; Corna E; Zunino F
Biochem Pharmacol; 2006 Mar; 71(6):791-8. PubMed ID: 16438941
[TBL] [Abstract][Full Text] [Related]
65. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
66. GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
Rae JM; Johnson MD; Cordero KE; Scheys JO; Larios JM; Gottardis MM; Pienta KJ; Lippman ME
Prostate; 2006 Jun; 66(8):886-94. PubMed ID: 16496412
[TBL] [Abstract][Full Text] [Related]
67. Molecular regulation of androgen action in prostate cancer.
Dehm SM; Tindall DJ
J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
[TBL] [Abstract][Full Text] [Related]
68. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.
Zoubeidi A; Rocha J; Zouanat FZ; Hamel L; Scarlata E; Aprikian AG; Chevalier S
Mol Cancer Res; 2009 Jan; 7(1):142-55. PubMed ID: 19147545
[TBL] [Abstract][Full Text] [Related]
69. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim IY; Kim BC; Seong DH; Lee DK; Seo JM; Hong YJ; Kim HT; Morton RA; Kim SJ
Cancer Res; 2002 Sep; 62(18):5365-9. PubMed ID: 12235008
[TBL] [Abstract][Full Text] [Related]
70. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
König JE; Senge T; Allhoff EP; König W
Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
[TBL] [Abstract][Full Text] [Related]
71. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.
Nickerson T; Miyake H; Gleave ME; Pollak M
Cancer Res; 1999 Jul; 59(14):3392-5. PubMed ID: 10416600
[TBL] [Abstract][Full Text] [Related]
72. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model.
Bisanz K; Yu J; Edlund M; Spohn B; Hung MC; Chung LW; Hsieh CL
Mol Ther; 2005 Oct; 12(4):634-43. PubMed ID: 16039164
[TBL] [Abstract][Full Text] [Related]
73. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
74. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.
Monet M; Lehen'kyi V; Gackiere F; Firlej V; Vandenberghe M; Roudbaraki M; Gkika D; Pourtier A; Bidaux G; Slomianny C; Delcourt P; Rassendren F; Bergerat JP; Ceraline J; Cabon F; Humez S; Prevarskaya N
Cancer Res; 2010 Feb; 70(3):1225-35. PubMed ID: 20103638
[TBL] [Abstract][Full Text] [Related]
75. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
[TBL] [Abstract][Full Text] [Related]
76. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1.
Choi ES; Shim JH; Jung JY; Kim HJ; Choi KH; Shin JA; Nam JS; Cho NP; Cho SD
Cancer Sci; 2011 Apr; 102(4):742-8. PubMed ID: 21241418
[TBL] [Abstract][Full Text] [Related]
77. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
78. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells.
Chen MW; Vacherot F; De La Taille A; Gil-Diez-De-Medina S; Shen R; Friedman RA; Burchardt M; Chopin DK; Buttyan R
Oncogene; 2002 Nov; 21(51):7861-71. PubMed ID: 12420223
[TBL] [Abstract][Full Text] [Related]
79. Pancratistatin induces apoptosis and autophagy in metastatic prostate cancer cells.
Griffin C; McNulty J; Pandey S
Int J Oncol; 2011 Jun; 38(6):1549-56. PubMed ID: 21424119
[TBL] [Abstract][Full Text] [Related]
80. Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer.
Xiao W; Zhang Q; Jiang F; Pins M; Kozlowski JM; Wang Z
Cancer Res; 2003 Aug; 63(15):4698-704. PubMed ID: 12907652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
